• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Prelude Therapeutics Incorporated

    4/29/26 4:11:35 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRLD alert in real time by email
    DEFA14A 1 for_filing_2026_defa14a.htm DEFA14A DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material Pursuant to §240.14a-12

    PRELUDE THERAPEUTICS INCORPORATED

    (Name of Registrant as Specified In Its Charter)

    N/A

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

    ☒

    No fee required.

    ☐

    Fee paid previously with preliminary materials.

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     


     

    img54669493_0.jpg

     

     

     

     

     

     


     

     

     

     

     

     

     

     

     

     

     

     

     

     

     


     

    img54669493_1.jpg

     

    Your Vote Counts! PRELUDE THERAPEUTICS INCORPORATED 2026 Annual Meeting Vote by June 8, 2026 11:59 PM ET. PRELUDE THERAPEUTICS INCORPORATED 175 INNOVATION BOULEVARD WILMINGTON, DE 19805 V94750-P51158 You invested in PRELUDE THERAPEUTICS INCORPORATED and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 9, 2026. Get informed before you vote View the Notice and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 26, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Vote Virtually at the Meeting* June 9, 2026 8:30 am Eastern Time Virtually at: www.virtualshareholdermeeting.com/PRLD2026 *Please check the meeting materials for any special requirements for meeting attendance.

     


    Get the next $PRLD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRLD

    DatePrice TargetRatingAnalyst
    9/19/2024$5.00Neutral → Buy
    H.C. Wainwright
    6/20/2024$3.00Equal Weight → Underweight
    Barclays
    3/13/2024$7.00Mkt Outperform
    JMP Securities
    2/20/2024$5.00Buy → Neutral
    H.C. Wainwright
    12/19/2023$10.00 → $4.00Equal-Weight → Underweight
    Morgan Stanley
    11/21/2022$8.00 → $6.00Neutral → Underperform
    BofA Securities
    9/9/2022$19.00 → $11.00Overweight → Equal-Weight
    Morgan Stanley
    7/29/2022$9.00Buy
    Jefferies
    More analyst ratings

    $PRLD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering

    WILMINGTON, Del., April 20, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD) ("Prelude" or the "Company"), a clinical-stage precision oncology company, today announced the pricing of its underwritten offering of 18,018,014 shares of its voting common stock (the "Common Stock") at a price of $4.44 per share, and, in lieu of Common Stock to investors who so chose, pre-funded warrants to purchase up to 2,252,252 shares of its Common Stock at a price of $4.4399 per pre-funded warrant, which represents the per share offering price for the Common Stock less the $0.0001 per share exercise price for each such pre-funded warrant. Before deducting the underwriting discounts a

    4/20/26 6:30:00 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026

    Data Demonstrate Potential for Differentiated Efficacy and Safety Profile, Including Complete Responses as Monotherapy in Multiple CDX and PDX Models of HR+/HER2- Breast Cancer  Prelude Remains on Track to File Investigational New Drug (IND) Application by mid-2026 and to initiate clinical trial in 2H 2026 WILMINGTON, Del., April 20, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a precision oncology company, today announced the presentation of new preclinical data from its lead development candidate, PRT13722. PRT13722 is being developed for the treatment of hormone receptor positive (HR+)/human epidermal growth factor receptor 2 (HER2-) breast cancer (BC). Ba

    4/20/26 6:00:00 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer

    WILMINGTON, Del., April 15, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD) ("Prelude Therapeutics" or the "Company"), a clinical-stage precision oncology company, today announced that Dr. Charles Morris will join the Company as Chief Medical Officer effective, April 20, 2026. "We are thrilled to welcome Dr. Charles Morris to Prelude Therapeutics as Executive Vice President and Chief Medical Officer," stated Kris Vaddi, Chief Executive Officer of Prelude Therapeutics. "With our two lead programs targeting myeloproliferative neoplasms and ER+ breast cancer advancing expected to enter into clinical development in 2026, Dr. Morris's deep clinical experience, track re

    4/15/26 7:30:00 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRLD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Prelude Therapeutics upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Prelude Therapeutics from Neutral to Buy and set a new price target of $5.00

    9/19/24 7:51:24 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prelude Therapeutics downgraded by Barclays with a new price target

    Barclays downgraded Prelude Therapeutics from Equal Weight to Underweight and set a new price target of $3.00

    6/20/24 7:37:20 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    JMP Securities initiated coverage on Prelude Therapeutics with a new price target

    JMP Securities initiated coverage of Prelude Therapeutics with a rating of Mkt Outperform and set a new price target of $7.00

    3/13/24 7:41:41 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRLD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Ra Capital Management, L.P. disposed of 1,407,000 shares (SEC Form 4)

    4 - Prelude Therapeutics Inc (0001678660) (Issuer)

    4/28/26 5:14:55 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Ra Capital Management, L.P. claimed ownership of 7,882,882 shares (SEC Form 3)

    3 - Prelude Therapeutics Inc (0001678660) (Issuer)

    4/28/26 5:13:28 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bonita David P bought $12,499,999 worth of shares (2,815,315 units at $4.44) (SEC Form 4)

    4 - Prelude Therapeutics Inc (0001678660) (Issuer)

    4/23/26 6:50:38 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRLD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bonita David P bought $12,499,999 worth of shares (2,815,315 units at $4.44) (SEC Form 4)

    4 - Prelude Therapeutics Inc (0001678660) (Issuer)

    4/23/26 6:50:38 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Orbimed Advisors Llc bought $12,499,999 worth of shares (2,815,315 units at $4.44) (SEC Form 4)

    4 - Prelude Therapeutics Inc (0001678660) (Issuer)

    4/23/26 6:48:25 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Chemistry Officer Combs Andrew bought $69,250 worth of shares (100,000 units at $0.69), increasing direct ownership by 26% to 480,123 units (SEC Form 4)

    4 - Prelude Therapeutics Inc (0001678660) (Issuer)

    3/27/25 4:40:54 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRLD
    SEC Filings

    View All

    SEC Form DEFA14A filed by Prelude Therapeutics Incorporated

    DEFA14A - Prelude Therapeutics Inc (0001678660) (Filer)

    4/29/26 4:11:35 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Prelude Therapeutics Incorporated

    DEF 14A - Prelude Therapeutics Inc (0001678660) (Filer)

    4/29/26 4:08:12 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Prelude Therapeutics Incorporated

    SCHEDULE 13G - Prelude Therapeutics Inc (0001678660) (Subject)

    4/28/26 5:16:19 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRLD
    Leadership Updates

    Live Leadership Updates

    View All

    Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer

    WILMINGTON, Del., April 15, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD) ("Prelude Therapeutics" or the "Company"), a clinical-stage precision oncology company, today announced that Dr. Charles Morris will join the Company as Chief Medical Officer effective, April 20, 2026. "We are thrilled to welcome Dr. Charles Morris to Prelude Therapeutics as Executive Vice President and Chief Medical Officer," stated Kris Vaddi, Chief Executive Officer of Prelude Therapeutics. "With our two lead programs targeting myeloproliferative neoplasms and ER+ breast cancer advancing expected to enter into clinical development in 2026, Dr. Morris's deep clinical experience, track re

    4/15/26 7:30:00 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors

    WILMINGTON, Del., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology company, today announced the appointment of Katina Dorton to its Board of Directors, effective today. Ms. Dorton has more than 30 years of industry expertise and leadership in healthcare and life sciences including service on several boards of public life science companies, executive financial leadership and investment banking. "Katina brings to Prelude an abundance of experience as a strategic and financial advisor to our leadership team," stated Kris Vaddi, Ph.D., Chief Executive Officer of Prelude. "We welcome her to our board and we look forward to

    10/17/25 7:30:00 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update

    Prelude remains on track for clinical data readouts and next steps for the PRMT5 program, MCL1 inhibitor PRT1419, and CDK9 inhibitor PRT2527 in 2H2022 Strong cash and cash equivalents of $266.2 million as of March 31, 2022, expected to fund operations into 2H2024 WILMINGTON, Del., May 10, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated ("Prelude") (NASDAQ:PRLD), a clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2022, and provided an update on recent clinical and development pipeline progress. "Prelude continues to make great progress in discovering and advancing a diverse pipeline of differentiated small molecu

    5/10/22 8:00:00 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRLD
    Financials

    Live finance-specific insights

    View All

    Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    Lead candidate from mutant selective JAK2V617F JH2 inhibitor program advancing with IND filing expected in the first quarter of 2026 Lead candidate from oral KAT6A selective degrader program advancing with IND filing expected in mid-2026 Preclinical data from JAK2V617F JH2 inhibitor program and CALR-targeted degrader antibody conjugate (DAC) program were both accepted for oral presentations at the American Society of Hematology (ASH) 67th Annual Meeting in December Current cash runway into 2027 based on preliminary estimates Company to host investor conference call and webcast on Wednesday, November 12, 2025 at 8:00 AM EST WILMINGTON, Del., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Prelude T

    11/12/25 7:01:00 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prelude Therapeutics Announces Strategic Business Update

    Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs JAK2V617F option agreement with Incyte, as previously announced, includes upfront payment of $35 million, a $25 million equity investment and $100 million if option is exercised Cumulative capital expected to fund planned operations into 2027 based on the Company's preliminary estimates, and potentially into the third quarter of 2028 if Incyte exercises option on JAK2 program Company to release third quarter 2025 financial results and conduct an investor conference call on November 12, 2025 WILMIN

    11/4/25 7:05:00 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

    -  Encouraging signs of anti-tumor activity including objective responses observed in patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal cancer in early PRT3789 monotherapy dose escalation -  At doses studied to date, PRT3789 was generally well-tolerated with no dose-limiting toxicities or study drug-related serious adverse events -  Company to host investor conference call and webcast on Friday, September 13, 2024 at 12:00 PM EST WILMINGTON, Del., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology company, today announced the first interim clinical

    9/13/24 10:00:00 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRLD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Prelude Therapeutics Incorporated (Amendment)

    SC 13G/A - Prelude Therapeutics Inc (0001678660) (Subject)

    2/13/24 1:34:34 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Prelude Therapeutics Incorporated (Amendment)

    SC 13G/A - Prelude Therapeutics Inc (0001678660) (Subject)

    2/12/24 5:30:07 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Prelude Therapeutics Incorporated (Amendment)

    SC 13G/A - Prelude Therapeutics Inc (0001678660) (Subject)

    2/12/24 4:26:50 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care